100 related articles for article (PubMed ID: 33826106)
1. Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019.
McEneny-King AC; Monteleone JPR; Kazani SD; Ortiz SR
Infect Dis Ther; 2021 Jun; 10(2):1045-1054. PubMed ID: 33826106
[TBL] [Abstract][Full Text] [Related]
2. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
Ortiz S; Pittock SJ; Berthele A; Levy M; Nakashima I; Oreja-Guevara C; Allen K; Mashhoon Y; Parks B; Kim HJ
Front Neurol; 2024; 15():1332890. PubMed ID: 38356884
[TBL] [Abstract][Full Text] [Related]
3. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
Vu T; Ortiz S; Katsuno M; Annane D; Mantegazza R; Beasley KN; Aguzzi R; Howard JF
J Neurol; 2023 Jun; 270(6):3129-3137. PubMed ID: 36890354
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Peffault de Latour R; Brodsky RA; Ortiz S; Risitano AM; Jang JH; Hillmen P; Kulagin AD; Kulasekararaj AG; Rottinghaus ST; Aguzzi R; Gao X; Wells RA; Szer J
Br J Haematol; 2020 Nov; 191(3):476-485. PubMed ID: 32449174
[TBL] [Abstract][Full Text] [Related]
5. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial.
Annane D; Pittock SJ; Kulkarni HS; Pickering BW; Khoshnevis MR; Siegel JL; Powell CA; Castro P; Fujii T; Dunn D; Smith K; Mitter S; Kazani S; Kulasekararaj A
Lancet Respir Med; 2023 Dec; 11(12):1051-1063. PubMed ID: 36958364
[TBL] [Abstract][Full Text] [Related]
6. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.
Vu T; Wiendl H; Katsuno M; Reddel SW; Howard JF
Neuropsychiatr Dis Treat; 2023; 19():2639-2655. PubMed ID: 38059203
[TBL] [Abstract][Full Text] [Related]
7. One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy: open-label extension of a randomized study.
Schrezenmeier H; Kulasekararaj A; Mitchell L; Sicre de Fontbrune F; Devos T; Okamoto S; Wells R; Rottinghaus ST; Liu P; Ortiz S; Lee JW; Socié G
Ther Adv Hematol; 2020; 11():2040620720966137. PubMed ID: 33178408
[TBL] [Abstract][Full Text] [Related]
8. Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria.
Brodsky RA; Peffault de Latour R; Rottinghaus ST; Röth A; Risitano AM; Weitz IC; Hillmen P; Maciejewski JP; Szer J; Lee JW; Kulasekararaj AG; Volles L; Damokosh AI; Ortiz S; Shafner L; Liu P; Hill A; Schrezenmeier H
Haematologica; 2021 Jan; 106(1):230-237. PubMed ID: 31949012
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
Hall FC; Cheriyan J; Cope AP; Galloway J; Wilkinson I; Bond S; Norton S; Banham-Hall E; Bayes H; Kostapanos M; Nodale M; Petchey WG; Sheeran T; Underwood J; Jayne DR;
Lancet Respir Med; 2023 Dec; 11(12):1064-1074. PubMed ID: 37977159
[TBL] [Abstract][Full Text] [Related]
10. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
[TBL] [Abstract][Full Text] [Related]
11. Monitoring Ravulizumab effect on complement assays.
Willrich MAV; Ladwig PM; Martinez MA; Sridharan MR; Go RS; Murray DL;
J Immunol Methods; 2021 Mar; 490():112944. PubMed ID: 33321132
[TBL] [Abstract][Full Text] [Related]
12. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.
Röth A; Rottinghaus ST; Hill A; Bachman ES; Kim JS; Schrezenmeier H; Terriou L; Urbano-Ispizua Á; Wells RA; Jang JH; Kulasekararaj AG; Szer J; Aguzzi R; Damokosh AI; Shafner L; Lee JW
Blood Adv; 2018 Sep; 2(17):2176-2185. PubMed ID: 30171081
[TBL] [Abstract][Full Text] [Related]
13. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study.
Kulasekararaj AG; Hill A; Rottinghaus ST; Langemeijer S; Wells R; Gonzalez-Fernandez FA; Gaya A; Lee JW; Gutierrez EO; Piatek CI; Szer J; Risitano A; Nakao S; Bachman E; Shafner L; Damokosh AI; Ortiz S; Röth A; Peffault de Latour R
Blood; 2019 Feb; 133(6):540-549. PubMed ID: 30510079
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Genge A; van den Berg LH; Frick G; Han S; Abikoff C; Simmons A; Lin Q; Patra K; Kupperman E; Berry JD
JAMA Neurol; 2023 Oct; 80(10):1089-1097. PubMed ID: 37695623
[TBL] [Abstract][Full Text] [Related]
15. Ravulizumab: A Review in Generalised Myasthenia Gravis.
Kang C
Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
[TBL] [Abstract][Full Text] [Related]
16. Ravulizumab: First Global Approval.
McKeage K
Drugs; 2019 Feb; 79(3):347-352. PubMed ID: 30767127
[TBL] [Abstract][Full Text] [Related]
17. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
18. Dose optimalization of subcutaneous ravulizumab is predicted to yield significant savings and to improve patient friendliness.
Ter Avest M; Langemeijer SMC; Blijlevens NMA; van de Kar NCAJ; Ter Heine R
Br J Clin Pharmacol; 2023 Mar; 89(3):1211-1215. PubMed ID: 36394176
[TBL] [Abstract][Full Text] [Related]
19. The potential of individualized dosing of ravulizumab to improve patient-friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs.
Ter Avest M; Langemeijer SMC; Schols SEM; Burger DM; van de Kar NCAJ; Blijlevens NMA; Kievit W; Ter Heine R
Br J Clin Pharmacol; 2021 Aug; 87(8):3359-3363. PubMed ID: 33512711
[TBL] [Abstract][Full Text] [Related]
20. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A; Nishimura JI; Nagy Z; Gaàl-Weisinger J; Panse J; Yoon SS; Egyed M; Ichikawa S; Ito Y; Kim JS; Ninomiya H; Schrezenmeier H; Sica S; Usuki K; Sicre de Fontbrune F; Soret J; Sostelly A; Higginson J; Dieckmann A; Gentile B; Anzures-Cabrera J; Shinomiya K; Jordan G; Biedzka-Sarek M; Klughammer B; Jahreis A; Bucher C; Peffault de Latour R
Blood; 2020 Mar; 135(12):912-920. PubMed ID: 31978221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
